287 related articles for article (PubMed ID: 31443961)
1. Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Kellokumpu-Lehtinen PL; Hjälm-Eriksson M; Thellenberg-Karlsson C; Åström L; Franzen L; Fransson AS; Leskinen MJ; Zeke M; Huttunen T; Ginman C;
Eur Urol; 2019 Dec; 76(6):823-830. PubMed ID: 31443961
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
[TBL] [Abstract][Full Text] [Related]
3. Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Oudard S; Latorzeff I; Caty A; Miglianico L; Sevin E; Hardy-Bessard AC; Delva R; Rolland F; Mouret L; Priou F; Beuzeboc P; Gravis G; Linassier C; Gomez P; Voog E; Muracciole X; Abraham C; Banu E; Ferrero JM; Ravaud A; Krakowski I; Lagrange JL; Deplanque G; Zylberait D; Bozec L; Houede N; Culine S; Elaidi R
JAMA Oncol; 2019 May; 5(5):623-632. PubMed ID: 30703190
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Hurwitz MD; Harris J; Sartor O; Xiao Y; Shayegan B; Sperduto PW; Badiozamani KR; Lawton CAF; Horwitz EM; Michalski JM; Roof K; Beyer DC; Zhang Q; Sandler HM
Cancer; 2017 Jul; 123(13):2489-2496. PubMed ID: 28323339
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
6. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Hussain M; Tangen CM; Thompson IM; Swanson GP; Wood DP; Sakr W; Dawson NA; Haas NB; Flaig TW; Dorff TB; Lin DW; Crawford ED; Quinn DI; Vogelzang NJ; Glode LM
J Clin Oncol; 2018 May; 36(15):1498-1504. PubMed ID: 29624463
[TBL] [Abstract][Full Text] [Related]
7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
8. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
9. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Carles J; Gallardo E; Doménech M; Font A; Bellmunt J; Figols M; Mellado B; Sáez MI; Suárez C; Méndez MJ; Maroto P; Luque R; de Portugal T; Aldabo R; Bonfill T; Morales-Barrera R; García J; Maciá S; Maldonado X; Foro P
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):344-352. PubMed ID: 30321689
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Sartor O; Karrison TG; Sandler HM; Gomella LG; Amin MB; Purdy J; Michalski JM; Garzotto MG; Pervez N; Balogh AG; Rodrigues GB; Souhami L; Reaume MN; Williams SG; Hannan R; Jones CU; Horwitz EM; Rodgers JP; Feng FY; Rosenthal SA
Eur Urol; 2023 Aug; 84(2):156-163. PubMed ID: 37179241
[TBL] [Abstract][Full Text] [Related]
13. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
[TBL] [Abstract][Full Text] [Related]
14. Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.
Kellokumpu-Lehtinen PL; Hjälm-Eriksson M; Thellenberg-Karlsson C; Åström L; Franzen L; Marttila T; Seke M; Taalikka M; Ginman C;
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):303-7. PubMed ID: 22546837
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
16. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Fizazi K; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houedé N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Lagrange JL; Chinet-Charrot P; Linassier C; Deplanque G; Beuzeboc P; Geneve J; Davin JL; Tournay E; Culine S
Eur J Cancer; 2012 Jan; 48(2):209-17. PubMed ID: 22119204
[TBL] [Abstract][Full Text] [Related]
17. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
Bitting RL; Healy P; George DJ; Anand M; Kim S; Mayer T; Winters C; Riggan C; Rasmussen J; Wilder R; Stein M; Frizzell B; Harrison MR; Zhang T; Lee WR; Wu Y; Koontz BF; Armstrong AJ
Eur Urol Oncol; 2021 Dec; 4(6):948-954. PubMed ID: 32063492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
